Navigation Links
CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
Date:10/24/2007

- Initial clinical trial results suggesting safety and clinical activity of CR011-vcMMAE reported at the AACR-NCI-EORTC International Conference -

BRANFORD, Conn., Oct. 24 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, announced that the first Phase I clinical trial results on CR011- vcMMAE, an antibody-drug conjugate (ADC) being developed for the treatment of metastatic melanoma, were presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, CA. To date, 25 patients with unresectable Stage III or IV malignant melanoma have been treated with CR011-vcMMAE in the Phase I dose-escalation portion of the trial.

Results from the ongoing trial suggest the CR011-vcMMAE is well-tolerated at doses up through 1.88 mg/kg with no dose-limiting toxicities noted. Dose- escalation continues with patients currently being enrolled into the 2.63 mg/kg cohort. Of the 25 patients treated with doses ranging from 0.03 mg/kg to 1.88 mg/kg, six patients achieved stable disease lasting up to 11 cycles, and four of the six patients demonstrated tumor shrinkage of up to 20%. Reversible neutropenia was the only drug-related Grade 3 or 4 adverse event, and appears to be dose-dependent. Evaluation of the pharmacokinetic results also suggest that CR011-vcMMAE can be given safely to achieve human plasma concentrations in the anticipated range of activity based on data from in vivo xenograft animal models.

Upon establishing the maximum tolerated dose (MTD), the trial is expected to expand directly into a Phase II study to further assess the activity of CR011-vcMMAE in up to 32 patients wit
'/>"/>

SOURCE CuraGen Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. CuraGen Presents Update on Clinical Development Program for Belinostat
2. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
3. CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... -- In part four of a blog series ... a strategic asset, Mary Baxter, MBA, RPh ., ... Innovation Delivery Solutions business, discusses how expanding patient access ... patients. "Every hospital pharmacist knows that filling ... in a value-based healthcare world," Baxter says. "For the ...
(Date:8/29/2014)... ROBLES, Calif. , Aug. 29, 2014  Pacific ... of its new website design . The main ... overhaul that showcases the company,s new services and content ... By implementing a new streamlined design, viewers can now ... metrics for health care practices and create a more ...
(Date:8/29/2014)... 2014 Pixcelldata, the innovative Irish ... announced a major new deal with Dutch based eX-Path, ... expert, Dr. Marius Nap . The ... Congress of Pathology which is taking placing between August ... London where Pixcelldata will demonstrate its ...
Breaking Medicine Technology:Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4PMDS Announces New Website 2Pixcelldata Announces New Deal with Dutch Tele-Pathology Specialists eX-Path Ahead of ECP 2014 2
... -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) ... from its ZFP Therapeutic program to develop SB-509, a ... endothelial growth factor (VEGF)-A gene as a treatment for ... drug was well-tolerated in subjects with ALS and that ...
... 17, 2010 The Amgen Foundation and Ashoka,s Changemakers today ... Empowerment competition and launched public online voting in search ... voices, and improve health outcomes. The ten ... from 277 entries received from 40 countries. Online ...
Cached Medicine Technology:Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting 2Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting 3Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting 4Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting 5Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting 6Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting 7Amgen Foundation and Ashoka's Changemakers Announce Finalists in Patients | Choices | Empowerment Competition 2Amgen Foundation and Ashoka's Changemakers Announce Finalists in Patients | Choices | Empowerment Competition 3Amgen Foundation and Ashoka's Changemakers Announce Finalists in Patients | Choices | Empowerment Competition 4
(Date:8/30/2014)... TX (PRWEB) August 30, 2014 Information ... Pros company to introduce better prices to consumers in ... plans can be found when using the open system ... national lookup system available to use this year can ... insurance based on general location and not from medical ...
(Date:8/30/2014)... Daily Gossip magazine reveals in its "Panic ... attacks under control with a simple and efficient method. ... this new method as an anxiety recovery program which ... general anxiety related disorders. , What makes this ... it can be accessed by users from the comfort ...
(Date:8/30/2014)... Ticket Down is a reliable ... in NYC. This popular ticket exchange has ... day session, evening session, courtside seats, grandstand seats, general ... Grand Slam Tournament. , The 2014 U.S. Open Tennis ... Tennis Championship: Men's/Women's 3rd Round - Session 11 Tickets ...
(Date:8/30/2014)... 2014 Seniors Guide, the comprehensive guide to ... on Alzheimer’s Disease, Dementia, and Memory Loss . , ... of being diagnosed with the Alzheimer’s, inspired Seniors Guide writers ... Me”. The movie, out on October 14, 2014, shows ... diagnosis of the disease – which inspires a final tour ...
(Date:8/30/2014)... In today’s world, a good night’s sleep has become ... apnea (a medical problem where the airway collapses during sleep ... the rest they need to face their daily challenges. ... million people in the United States alone have sleep apnea. ... of those treated, many cannot tolerate their prescribed medical device ...
Breaking Medicine News(10 mins):Health News:Term Life Insurance Rates Now Found Nationally by New Insurer Finder Tool 2Health News:Panic Away Review Reveals New Natural Remedy for Anxiety Patients 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 3Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 4Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 5Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... white paper that examines various state initiatives to expand access ... and Congress in support of state efforts, was distributed today ... The paper, State Experimentation with Reforms to Expand Access to ... part of any state-based reform. It is a summary of ...
... Ill., Sept. 14 The board of,directors of Abbott ... share. This marks the 335th consecutive quarterly dividend ... is payable Nov. 15, 2007, to,shareholders of record at ... About Abbott Abbott (NYSE: ABT ) is ...
... 14 As the political turmoil,surrounding stem cells rages ... and treatment - that saved his life. John E. ... -, http://www.authorhouse.com ), recounts the courageous five-year battle the,author ... cancer. Settling into a comfortable retirement with his ...
... of Texas Medical Branch at Galveston are trying to ... can also be used to delay delivery in expectant ... would give hope to hundreds of thousands of women ... drug, Digibind, has been prescribed for over 20 years ...
... Sept. 14 People,s United,Financial (Nasdaq: PBCT ) ... Klein, had undergone surgery to address a recurrence of,cancer ... surgery. He reported,in an e-mail to all employees that ... bank in early October. He stated that he is ...
... - Philly-Area Employers Get Moving by Putting on ... AstraZeneca continues,its fight against sedentary lifestyles by ... in Philadelphia to promote,walking and other healthy habits ... a Start! "walkforce" team to participate in,today,s Philadelphia ...
Cached Medicine News:Health News:Internal medicine physicians recommend key elements to guide state initiatives 2Health News:Internal medicine physicians recommend key elements to guide state initiatives 3Health News:The Fight for His Life: Author, Family Battle Disease and Challenge Politics in the Face of Survival 2Health News:AstraZeneca Joins Local Walking Movement 2Health News:AstraZeneca Joins Local Walking Movement 3Health News:AstraZeneca Joins Local Walking Movement 4
... The BioPlex 2200 system is ... platform that can deliver up to ... will initially include a panel of ... in development are in the areas ...
... ASR contains primers and a FAM-labeled probe targeting ... as well as primers and an Alexa 532-labeled ... of HSV Type 2. This ASR requires an ... Alexa reporter dyes like the Cepheid SmartCycler System. ...
... and a FAM-labeled probe that is designed to ... Type 1 and Type 2 polymerase gene. This ... FAM reporter dye like the Cepheid SmartCycler System. ... is comprised of a series of easy-to-use primer ...
... The Stratus CS Analyzer, designed for Acute Care ... your laboratory and near patient setting. It's a ... or D-Dimer results from a whole blood sample ... 3 step process load sample and rotor, ...
Medicine Products: